{"disease":{"id":"non-hodgkin-lymphoma-refractory-relapsed","name":"non hodgkin lymphoma refractory relapsed"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06119685","title":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT05798897","title":"Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":79,"lead_sponsor_name":"Marker Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03755154","title":"Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":60,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT07271121","title":"Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"King Hussein Cancer Center","has_results":false},{"nct_id":"NCT06343311","title":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Estrella Biopharma, Inc.","has_results":false},{"nct_id":"NCT05360238","title":"Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Mustang Bio","has_results":false},{"nct_id":"NCT05618925","title":"Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT04150913","title":"A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Marcela V. Maus, M.D.,Ph.D.","has_results":true},{"nct_id":"NCT07478848","title":"Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT03774654","title":"CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT05054257","title":"CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institute of Hematology and Blood Transfusion, Czech Republic","has_results":false},{"nct_id":"NCT06334991","title":"Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT03488251","title":"PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Molecular Templates, Inc.","has_results":true},{"nct_id":"NCT02181478","title":"Intra-Osseous Co-Transplant of UCB and hMSC","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}